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Abstract 
 
Bacillus anthracis, a spore forming Gram (+) bacterium, is considered one of the most lethal biological 
weapons due to its highly pathogenic nature, easy production, preservation, and to the possibility of 
being aerosolized and sprayed. The fact that antibiotics are ineffective against the spores and the released 
toxins, makes it a serious threat 1,2.In addition, development of antimicrobial resistance has become a 
worldwide problem, as the impact of antibiotics is diminishing due to progressive rise of resistance to 
the available antimicrobial drugs 3.   
It was previously described the importance of the bacteria membrane’s integrity in its life - the cell 
envelope cannot change without significant consequences to the bacteria life. Also, the development of 
resistance becomes extremely difficult 4. For this reason, the essentiality of cell membrane makes it a 
promising target for new antibiotics.  
In order to target B. anthracis membrane, our research group has investigated the use of carbohydrate-
based surfactants as potential antibiotics since these amphiphilic compounds are known to be able to 
interact with the cell membrane lipid bilayer 5. Hence, a library of alkyl glycosides was synthesized 
varying deoxygenation pattern, alkyl chain, sugar stereochemistry, anomeric configuration and atom 
linking the alkyl chain to the saccharide moiety 6–10. The compound that showed the best results was an 
O-glycoside,  the dodecyl 4,6-dideoxy-α-D-xylo-hexopyranoside, which was active against B. cereus, E. 
faecalis and B. anthracis (strains: pathogenic, sterne and ovine) with MIC = 12.6 μM. Comparing to 
chloramphenicol, the control used in the biological assays, the MIC value revealed to be half of the MIC 
showed by the control (MIC = 25 μM). Also C-glycosides were found less toxic compounds on Caco-2 
cells than the corresponding O- and S-glycosides 9.  
The aim of the presenting dissertation was to explore the first synthetic route towards dodecyl 4,6-
dideoxy-α-D-xylo-hexopyranoside, the C-glycoside analogue to the O-glycoside previously described. 
Three synthetic pathways were investigated, using either the naturally occurring D-glucose or its methyl 
glucoside as starting materials. When starting from D-glucose, it was regioselectively protected with a 
4,6-O-benzylidene group while benzyl groups were protecting positions 1, 2 and 3. Since the reaction 
outcome of the acetal protecting group with N-iodosuccinimide was not successful possibly due to the 
reactivity of the benzyl protecting groups, other attempts were tried and the  desired compound – the C-
glycoside with the 4,6-dideoxy pattern (19) was obtained in 13% overall yield. Cytotoxicity tests are to 
be performed and biological assays are on-going in order to determine this C-glycoside efficacy towards 
B. anthracis. 
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Resumo 
 
Bacillus anthracis, uma bactéria Gram (+) existente na forma de esporos, é considerada uma das armas 
biológicas de maior carácter letal devido à sua natureza altamente patogénica, à facilidade da sua 
produção e preservação bem como a possibilidade de os esporos serem pulverizados. O facto de os 
antibióticos não serem efetivos quando usados contra os esporos ou contra as toxinas libertadas pela 
bactéria, torna-a um problema sério 1,2. Para além disso, o desenvolvimento de resistência a 
antibacterianos tornou-se um problema grave à escala mundial, com o impacto da evolução dos 
antibióticos a diminuir face ao aumento progressivo da resistência dos patógenos às terapêuticas 
disponíveis 3. 
A importância da integridade da membrana bacteriana foi descrita anteriormente, onde se afirmou que 
o envelope celular não muda sem gerar consequências significativas na vida da bactéria. Ainda, o 
desenvolvimento de mecanismos de resistência torna-se extremamente difícil. Por esta razão, a 
essencialidade da membrana celular torna-a um alvo promissor para novos antibióticos 4. 
Tendo a membrana da bactéria B. anthracis como alvo a atingir, o nosso grupo de investigação está 
focado no desenvolvimento de carboidratos surfactantes como potenciais antibióticos, uma vez que se 
sabe que este tipo de moléculas anfifílicas interage com a membrana lipídica das células 5. Deste modo, 
foi sintetizada uma pequena biblioteca de C-glicósidos de alquilo com padrão de desoxigenação 
variável, diferentes cadeias alquílicas, estereoquímica do monossacárido, configuração anomérica e 
átomo que liga a cadeia alquílica ao glicósido 6–10. O composto que demonstrou melhores resultados foi 
um O-glicósido, 4,6-didesoxi-α-D-xylo-hexopiranósido de dodecilo, que revelou ser ativo contra as 
bactérias B. cereus, E. faecalis e B. anthracis (estirpes: patogénica, sterne e ovino) com MIC = 12.6 μM. 
Comparando com os resultados demonstrados aquando do uso de cloranfenicol, contro lo usado nos 
testes biológicos, o valor de MIC do O-glicósido revelou ser cerca de metade do valor de MIC do 
controlo (MIC controlo = 25 μM). Ainda, os C-glicósidos sintetizados demonstraram ser menos tóxicos 
para a linha celular Caco-2 do que os correspondentes O- e S-glicósidos 9. 
O objetivo da dissertação apresentada foi o da exploração da primeira via sintética do composto 4,6-
didesoxi-α-D-xylo-hexopiranósido de dodecilo, o C-glicósido análogo ao O-glicósido previamente 
descrito. Foram investigados três esquemas sintéticos, usando a D-glucose ou o seu análogo metilado 
como produtos de partida. O esquema sintético A partiu da D-glucose, cuja proteção dos grupos -OH 
livres foi conseguida com a introdução regiosseletiva do grupo 4,6-O-benzilideno e de grupos benzilo 
nas posições 1, 2 e 3. Uma vez que a redução do grupo benzilideno com N-iodosuccinimida não foi 
conseguida com sucesso, possivelmente devido à reatividade dos grupos benzilo, o esquema sintético B 
foi adotado. Após várias reações de proteção/desproteção dos hidroxilos da glícona, C-glicosilação da 
posição anomérica e elongação da cadeia alquílica, o derivado de glicósido desejado – o C-glicósido 
com o padrão de desoxigenação 4,6-didesoxi (19) foi obtido com um rendimento total de 13%. Os 
resultados dos testes de citotoxicidade são esperados de modo a confirmar a hipótese, inicialmente 
proposta, de que o C-glicósido é menos tóxico que o seu análogo O-glicósido. Além disso, os testes 
biológicos estão em curso para que seja determinada a eficácia deste C-glicósido contra a bactéria B. 
anthracis. 
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1.1 Carbohydrates 
Carbohydrates are one of the most abundant molecules on Earth and essential to life prosperity. In early 
Earth life, these molecules played a key role in the evolution of the living organisms.  
In the presence of sun light, during the photosynthesis process, it is possible to combine water and carbon 
dioxide to give rise to carbohydrates and molecular oxygen (equation 1 .1). The energy, stored as 
C6H12O6 structure type, is then usable by non-photosynthesizing organisms in processes known as 
glycolysis and respiration. It is suggested that in ancient earth, the amount of available oxygen was 
scarce and therefore the carbohydrates were broken down through anaerobic glycolysis, to form 
adenosine triphosphate (ATP) and lactic acid (equation 1.2). As only a limited amount of energy was 
available - 2:1 (ATP/ C6H12O6), life on earth remained primitive. However, in the course of time, with 
the increase of the concentration of molecular oxygen in the atmosphere, the living organisms evolved 
to completely oxidize the carbohydrates, through the respiration process. As a consequence, the amount 
of usable energy increased significantly - 38:1 (ATP/ C6H12O6) (equation 1.3), leading to a burst in the 
number and complexity of living organisms.  
In today’s life, certain carbohydrates provide up to 60% of the total of calories of a human diet , being 
glucose extremely important, with blood concentration of about 1g/L11. 
 
 
 
 
 
 
Apart from its importance as energy suppliers, carbohydrate also exist as polymers, which serve as 
structural components of bacteria and plants’ cell walls, being the case of cellulose. Other carbohydrates 
are crucial in biological processes as they mediate cellular adhesion and recognition, as mentioned in 
section 1.2.3, page 11, where it will be discussed the use of carbohydrates as antibiotics. 
The study of the carbohydrates arises from the 19th century, where it was thought that they were carbon 
hydrates, being their empirical composition expressed by the general formula Cn(H2O)n. Later on, it was 
found that carbohydrates are, in fact, polyhydroxy aldehydes and ketones but their derivatives were also 
included in this class of compounds 11,12.  
In fact, according to IUPAC Recommendations, the generic term “carbohydrate” includes 
monosaccharides, oligosaccharides, polysaccharides and substances derived from monosaccharides’ 
carbonyl group reduction, oxidation of one or more terminal groups or replacement of one or more 
hydroxy groups by a hydrogen atom or an amino, thiol or other heteroatomic group.  The term “sugar” 
is commonly used when referring to monosaccharides and oligosaccharides with low molar mass12. 
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1.1.1 -D and -L configuration 
Emil Fischer gave a major contribution to this field of organic chemistry by identifying, characterizing 
and synthesizing monosaccharides. Very briefly, with the introduction of the concept of stereochemistry, 
by van’t Hoff and Le Bel in 1874, Fischer was able to understand carbohydrates isomerism and proposed 
what is known as the Fischer projection. This projection consists in representing monosaccharides 
through a central carbon chain, with the carbonyl group on top and the hydroxy groups as substituents, 
pointing left or right, along the vertical chain (see Figure 1.1)11–14.  
Melting point and optical rotation were the essential techniques used to identify monosaccharides. In 
the case of optical rotation, dextrorotation occurs when the compound analysed deviates the plane-
polarized light to the right (expressed as (+)) and levorotation occurs when the plane-polarized light is 
deviated to the left (expressed as (-))13. 
Only being confirmed later on, Fischer proposed that the dextrorotatory glucose (D-glucose) would have 
the hydroxy group in C-5 pointing to the right in the carbon backbone (see Scheme 1.1). In 1906, 
Rosanoff elected glyceraldehyde as the reference molecule to do the D- and L- attributions, i.e., any 
sugar derived from D-glyceraldehyde by increasing the length of the sugar backbone belongs to the D- 
series, whereas any sugar derivable from L-glyceraldehyde by increasing the length of the sugar 
backbone belongs to the L- series (see Figure 1.1). Although the convention proposed by Rosanoff 
continues in use, now it is known that a compound with D- configuration may not be dextrorotatory12,13. 
When accessing the absolute configuration of a sugar with two or more chirality carbons, the last chiral 
carbon is used as term of comparison with glyceraldehyde (see Figure 1.1 for numbering of carbons in 
Fischer projection)13,14. 
 
 
 
 
Figure 1.1. From left to right, D- and L-glyceraldehyde. 
 
1.1.2 Mutarotation  
In 1846, the term “mutarotation” had been introduced by Dubrunfaut, as he realized that the optical 
rotation of a pure enantiomer of glucose changes with time. He observed that a freshly prepared solution 
of α-D-glucopyranose in water has a specific rotation of about +112º, which decreases with time to +52º. 
Likewise, a freshly prepared solution of β-D-glucopyranose in water has a specific rotation of about 
+19º, which also decreases with time to +52º. This value does not correspond to a new structure of 
glucose, as initially thought, but to the mixture of both α and β isomers in equilibrium in the solution  
(see Scheme 1.1) 12,13. 
Still in late 19th century, von Baeyer and Tollens also suggested the existence of two cyclic forms of the 
D-glucose, resulting from the nucleophilic attack of one of the hydroxy groups to the carbonyl moiety, 
giving rise to the two isomeric forms (α and β). Depending hydroxy group attacking the carbonyl, 
glucose would cyclize as a five or a six-membered ring (see Scheme 1.1) 13,14. 
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Scheme 1.1. Representation of the equilibria causing D-glucose mutarotation (equilibrium between acyclic form and the α and 
β anomers of D-glucose of both pyranose and furanose forms) 12,13. 
In order to facilitate the representation of sugars, in 1926, Haworth suggested a simpler representation 
of a six membered ring glucose – what is now known as Haworth projection, shown in Figure 1.2. In 
1955 another representation, still in use today, was proposed by John A. Mills (see Figure 1.2) 13,14.  
 
 
 
 
 
 
 
 
It is known that when chemical species are in rapid equilibrium, the concentration of each species 
depends on its relative energy. In fact, D-glucose exists as a hemiacetal ring and its isomers, depicted in 
Scheme 1.1, exist in equilibrium in different ratio. The amount of the pyranose form is much higher than 
the amount of the furanose form, where its equilibrium concentration is only about 0.11% and 0.28% (α 
and β-furanose respectively) of the total equilibrium concentration of glucose. On its turn, the acyclic 
form only accounts for a trace of the total glucose (about 0.004%). And even the two pyranose anomers 
exist in different proportions, due to their different stability, being the α and β, 37.64% and 61.96% 
respectively 15,16. 
The low thermodynamic stability of the open chain explains its appearance in vestigial quantity as well 
as the preference for the six-membered ring form over the five-membered ring form, where the torsional 
strain tends to be minimized. As for entropy, it is more favourable to occur an intramolecular reaction 
than an intermolecular one, explaining the cyclization of the sugars instead of the nucleophilic attack by 
a hydroxy group of one molecule to the carbonyl moiety of another molecule. Also, the β anomer is 
more stable since all the substituents in the sugar are in equatorial position, minimizing electrostatic 
repulsions between the ring’s substituents, whereas in the α anomer, the hydroxy group in the anomeric 
position is in axial position 13–16. Note that for pyranose rings, it is quite common that the α anomer has 
higher stability than the β one, being this stabilization effect named as anomeric effect (mentioned in  
page 6).  
Figure 1.2. From left to right, representation of Mills and Haworth projection of α-D-
glucopyranose. In the first one, the ring is visualized in the plane of the paper, while the 
substituents are represented with “wedge” (above) or dashed (below) notation. In the 
second one, the ring is viewed front edge-on the paper, across the C2-C3 wedge-bond, with 
the substituents pointing “up” or “down” the hexagon. 
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1.1.3 Conformation 
The stability of the pyranose forms is related to their special rearrangement. In the equilibrium between 
D-glucopyranose anomers and D-glucofuranose anomers, the most stable form is the β-D-glucopyranose 
showing the 4C1 chair conformation, in which all hydroxy groups are in equatorial orientation  (see 
Figure 1.3).  
 
 
 
 
In early 1900, Hassel demonstrated that the cyclohexane ring was not planar but it showed a non-planar 
shape, similar to a chair. Now it is well known that there are several conformations of cyclohexane in 
rapid equilibrium, the boat conformation (B), the chair conformation (C) and another degenerate chair 
conformation, where there is interchange of the axial/equatorial bonds 15.  
The carbon-heteroatom bond length is shorter than the carbon-carbon bond length, as well as the carbon-
heteroatom-carbon angles are generally smaller than the corresponding C-C-C angles. As a 
consequence, the substituents in a heterocycle have higher preference for the equatorial positions when 
compared to the cyclohexane ring, in order to minimize electrostatic repulsions, explaining the 
preference for 4C1 conformation over the 
1C4 conformation (see Figure 1.3) 
17.   
However, being the chair conformation the spacial rearrangement preferred by D-glucopyranose, there 
are other possible conformations for pyranose rings – half chair (H) and skew (S). Although worth 
mentioning, these last conformations are higher energy forms, only existing in vestigial quantity, when 
converting the chair conformations in one another. In the case of furanose ring, there are two main 
possible conformations – envelop conformation (E) and twist conformation (T) 15,16.  
Lemieux and Karplus suggested, by 1H NMR, that it is possible to distinguish both 4C1 and 
1C4 chair 
conformations when measuring the coupling constants between H-2 and H-3. Owing to the relationship 
between the magnitude of the coupling constant and the size of the torsional angle between vicinal 
protons, in the first form, 3J2,3 is higher (in the order of 9Hz – 10Hz) since H-2 and H-3 are in trans 
diaxial position, with a dihedral angle near 180º while in the second form this coupling constant should 
be between 1Hz – 2 Hz. This rule is applied when determining the chirality centers’ configuration of the 
sugars using NMR analysis (see Figure 1.4) 15,16.  
 
 
 
 
 
 
 
 
Figure 1.3. Representation of the 4C1 and 
1C4 chair 
conformation of β-D-glucopyranose (from left to right, 
respectively) 
Figure 1.4. Representation of the coupling constant (in Hertz) of vicinal 
protons in function of their dihedral angle (in degrees), proposed by 
Karplus. Figure adapted from the literature 11. 
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1.1.4 Anomeric effect 
One of the most important observations made when studying the carbohydrates was that the presence of 
the endocyclic oxygen in the monosaccharide ring deeply influences the anomeric position, being quite 
common the preference for the formation of the α anomer over the β anomer. This phenomenon was 
named as anomeric effect, in 1958, by Lemieux 15.  
Briefly, this effect has been explained using an electrostatic and a stereoeletronic interpretation. 
In 1955, it was first proposed that the existence of a repulsive dipolar interaction between the lone pair 
of electrons of the endocyclic oxygen and the exocyclic heteroatom in equatorial position would be 
relieved if the substituent adopted an axial configuration (see Figure 1.5).  
 
 
 
 
 
 
More recently, it has been suggested the importance of a nonclassical CH⋯X hydrogen bond between 
the axial group at C-1 and the syn-axial hydrogens in C-3 and C-5 in the stabilization of the axial anomer 
(see Figure 1.6 a) 17–19. In fact, the magnitude of the anomeric effect is dependent on the solvent used, 
as more polar solvents stabilize the equatorial configuration. Also, the electronegativity of the 
substituent is decisive, being the magnitude of this eff ect increased in the presence of more 
electronegative atoms 17,18. On the other hand, the reverse anomeric effect occurs when the anomeric 
substituent has lower electron density, where the β anomer is preferentially formed.  
 
 
 
 
 
 
 
On the stereoeletronic interpretation, this effect is explained by the hyperconjugative interaction 
involving electron delocalization from the endocyclic oxygen to the adjacent C1 – X antibonding orbital. 
The stabilization effect arises from the fact that, in the axial anomer, the orbital with the lone pair of 
electrons in the oxygen and the mentioned antibonding orbital are antiperiplanar (see Figure 1.6 b). Also 
important is the delocalization of the hydrogen (H – C – X) electron density into X, being a major 
contribution to the anomeric effect. It results from the lengthening of the C – X bond, in order to 
minimize the repulsion with the ring atom and favouring the interaction between the endocyclic oxygen 
and a more positive hydrogen. Experimentally, it can be measured the lengthening of the C – X bond 
and the shortening of the C – O bond in cases that display an anomeric effect 11,13,14,17. 
Figure 1.5. Electrostatic repulsion between the endocyclic heteroatom 
and the substituent in β and α configuration (from left to right, 
respectively) in a 4C1 conformation. Adapted from the literature 
17. 
Figure 1.6. a) Representation of the nonclassical CH⋯X hydrogen bond between 
the axial group at C-1 and the syn-axial H-3 and H-5, adapted from the literature 
18,19. b) Representation of the stereoeletronic interpretation of the anomeric effect in 
a 4C1 conformation, adapted from the literature 
17. 
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1.1.5 Glycosylation  
Carbohydrates exist as mono-, oligo- and polysaccharides or associated to proteins or lipids, 
glycoproteins and glycolipids respectively. Hence, it is implied a coupling reaction between a glycosyl 
donor and a glycosyl acceptor to form a new glycoside. 
As referred in IUPAC Recommendations, glycosides are defined as mixed acetals/ketals derived from 
cyclic forms of monosaccharides, being included derivatives in which the anomeric hydroxy group has 
been replaced by a -OR, -NR1R2, -SR, -SeR, or -CR1R2R3 group, where R is arbitrary 12, while when 
replaced by -NR1R2, or -CR1R2R3 groups, these compounds should not be named as glycosides since 
their reactivity is not similar to that of acetals.  
In a typical glycosylation reaction, one of the building blocks (glycosyl donor) has the anomeric position 
substituted with a good leaving group, while the other (glycosyl acceptor) has one functional group that 
will act as nucleophile (independently of being sugar or non-sugar derived) (see Scheme 1.2) 11–15. In 
the final glycoside, both building blocks are linked through a glycosidic bond and the final glycoside is 
named either as O-glycoside (-OR), thioglycoside (-SR), selenoglycoside (-SeR), while glycosylamine 
(-NR1R2) and C-glycosyl compounds (-CR1R2R3) are generic terms used for the latter compound 
families. It is common to refer to the carbohydrate residue as glycone, and to the glycosyl acceptor 
residue, aglycone (in cases where the nucleophile is not a monosaccharide) 12.  
All of the above described glycosidic bonds have different susceptibility to hydrolysis,  typically, C-
glycosyl compounds are hydrolysis stabile, as ethers. C-glycosyl compounds will be discussed in section 
3.1.2, page 24. 
In 1983, Emil Fischer made an innovative breakthrough when activating the hemiacetal function of 
glucose and replacing the anomeric hydroxy group with a methoxy group, using methanol  in the 
presence of an acid catalyst. This work was not pioneer, as methyl glucoside had been already 
synthesized before, however it was performed in an unprotected sugar, which was a notorious mark 20. 
In fact, one of the major challenges in carbohydrate synthesis is the control of regioselectivity, since 
there are multiple hydroxy groups, able to react.  
In order to overcome that issue, generally, all the functional groups in both glycosyl donor and acceptor 
are temporarily masked with adequate protecting groups, except for the reactant moieties. There are, 
however, cases of glycosylation reactions using totally or partially unprotected glycosyl 
donors/acceptors, under specific reaction conditions 20–22   
The other major challenge is the stereoselectivity control, since reaction leads to two stereoisomers due 
to the formation of a new chirality centre. This, however, can be managed with the correctly chosen 
carbohydrate protecting groups and leaving group, catalyst, solvent and temperature 3,20,23–25. 
Although not completely understood yet, it is agreed that glycosylation reactions undergo either a SN1 
or SN2 type mechanism (see Scheme 1.2). Usually, prior to nucleophilic attack, there is displacement of 
the anomeric leaving group (-LG), assisted by the catalyst in solution. It is then formed an intermediate 
oxycarbenium ion. There are cases where the glycosyl donor is equipped with an acyl derived group in 
position 2, which in turn can participate in the reaction by forming a cyclic acyloxonium intermediate. 
This intermediate exists in rapid equilibrium with the oxycarbenium ion, stabilizing it. Hence, the 
following nucleophilic attack occurs either on the top or the bottom face of the sugar, depending on the 
steric hinderance caused by the new intramolecular cycle – the neighbouring group effect. In the case 
of D-glucose, since the substituent in C-2 is in an equatorial position, the attack would occur on the top 
face, forming the β anomer as major product 20–23,25.  
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The described mechanism is similar to a typical SN2 reaction, however, when the stereocontrol of the 
reaction is diminished, for instance, due to poor nucleophilic nature of the glycosyl acceptor or weak 
assistance of the substituent in C-2, the glycosylation reaction may adopt a mechanism similar to an SN1 
reaction, with the nucleophilic attack direct to the oxycarbenium intermediate. In this case, the anomeric 
effect is prevalent, originating the α isomer as major product (see section 1.1.4, page 6 for anomeric 
effect enlightenment) 20,25.  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Scheme 1.2. Strategies for anomeric stereoselective control, exemplified for the formation of an 
O-glycoside. P refers to a generic protecting group, LG stands for leaving group and R for a 
generic group function. Adapted from the literature 20. 
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1.2 Antibiotics 
The control of bacterial infections has been well documented in the past centuries in Greece, Egypt and 
China. Nevertheless, until mid-20th century, bacterial infections that we now consider straightforward 
to treat – such as pneumonia or diarrhoea – that are caused by bacteria, caused human death in the 
developed world 3,26.  
In 1928, Alexander Fleming transformed medicine with the discovery of the first antibiotic – the 
penicillin. After struggling with purification issues, in the 1940s, the first prescription of penicillin was 
made. Later, it was called the “wonder drug” as, coinciding with the World War II, it became the  
treatment of choice amongst the bacterial infected soldiers, saving lives 3,26. 
Antibiotics are bacterial or fungal metabolites which are able to inhibit the growth of other 
microorganisms, including natural, semi-synthetic or synthetic antibacterial substances. They can be 
classified as bactericides – directly killing the microorganisms or bacteriostatic – slowing down bacteria 
growth/reproduction 5,27. 
Despite this, shortly after penicillin’s discovery, in 1940, Abraham and Chain reported that a specific  
Escherichia Coli. strain was able to inactivate this antimicrobial compound by producing penicillinase 
28. Over time, several strains of other types of bacteria also became resistant to penicillin. For instance, 
by 1960, 80% of community and hospital acquired strains of Staphylococcus aureus were penicillin 
resistant. By 2003, more than 90% of staphylococcal isolates produced penicillinase, regardless of the 
clinical setting 26,29. 
The imprudent and excessive use of antibiotics in both humans and animals, allied with natural resilience 
mechanism of bacteria, rely as the major cause of resistance evolution – the sensitive bacteria are killed 
while resistant pathogens persist and reproduce through different mechanisms, thriving through natural 
selection 3,26. 
Hence, the emergence and propagation of the resistant bacteria strains led to the development of novel 
types of antimicrobials. Throughout the past 75 years, several classes of antibiotics were identified – β-
lactams (where it is included the several types of penicillin), sulphonamides, tetracycline, glycopeptides, 
phosphonates, lipopeptides amongst others. However, bacteria have developed resistance to them, 
through different mechanisms of resistance – either the antibiotic is pumped out by the bacteria by efflux 
pumps on the cell wall or there is enzymatic breakdown/modification of the antibiotic or even 
modification/multiplication of the target 3,26.  
Antimicrobial resistance (AMR) is a serious global threat and, unfortunately, the impact of antibiotics 
is now diminishing due to the progressive rise of resistance, and this is observed amongst all 
antimicrobial drugs. There are bacterial species resistant to all known antibiotics (multidrug-resistant 
bacteria - MDR), leaving both humans and animals vulnerable to common infections 3. Hence, the 
development of new antimicrobials with novel mechanisms of action is key. 
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1.2.1 Gram-positive and Gram-negative bacteria 
By 1884, Christian Gram classified nearly all bacteria in two large groups – Gram-positive and Gram-
negative, based on the structural differences of their cell envelope. Commonly referred as examples, are 
Escherichia coli, a Gram-negative bacteria and Staphylococcus aureus, a Gram- positive bacteria 28,30.  
The outer membrane (OM) in Gram (–) bacteria is a lipid bilayer essentially composed by glycolipids, 
principally, lipopolysaccharides (LPS), which are inflammation mediators to the human innate system. 
The OM plays a significant role in protecting the bacteria from the exterior environment, indirectly 
stabilizing the inner membrane. For this reason, the peptidoglycan wall is very thin, although, because 
of its rigidity, it defines the cell shape 28,30.  
On the other side, Gram (+) bacteria lack the OM and in turn have a thicker peptidoglycan wall. In this 
wall, and accounting for up to 60% of the mass of Gram (+) bacteria, there are teichoic and lipoteichoic 
acids, polysaccharides covalently attached to the peptidoglycan and anchored to membrane-embedded 
glycolipids. These polymers play a major role in the membrane integrity 28,30.  
The bacterial cell membrane is independent of the cell’s metabolic status, however it is crucial for cell 
survival as it regulates homeostasis and houses vital proteins. Hence, the cell envelope cannot change 
without significant consequences to the bacteria life and also, the development of resistance becomes 
extremely difficult. For this reason, the essentiality of cell membrane makes it a promising target for 
new antibiotics. Also, molecules targeting cell membrane may act together with conventional drugs, as 
they can compromise cell envelope permeability and integrity, increasing drugs’ efficacy 4. 
 
1.2.2 Bacillus anthracis   
Bacillus anthracis (B. anthracis), the causative agent of anthrax, is a Gram-positive spore forming, non-
motile bacterium that belongs to Baccillus cereus (B. cereus) sensu lato group. This bacterium exists as 
two forms, as spores (outside the host) or as vegetative cells (inside the host)31. The spore is normally 
encountered in the soil, where it can remain, in anaerobic conditions, viable for decades, as it is resistant 
to extreme environmental conditions, such as high temperature, pressure, pH, UV and nutrient deficit. 
Its half-life is estimated of about 100 years 31–33.  
In the worst cases, the cycle of life starts with spores’ germination as they enter the hosts’ bloodstream, 
a nutrient rich media, where they regain metabolism and start vegetative growth, with further bacteria 
multiplication. B. anthracis’ virulence is controlled by the presence of a poly-γ-D-glutamic acid capsule 
and the later released tripartite toxin. In fact, a specific strain of B. anthracis which have no capsule but 
carries the toxin, is considered avirulent and it is even used in the production of vaccines. The capsule 
itself is not toxic, however it contributes significantly in establishing the infection as it mimics the host 
immune system, escaping phagocytes ability to engulf and destroy bacteria. The disease spread is then 
controlled by the bacteria’s toxin releasing. The infection may take only a few days to be lethal to the 
host organism, whose infected blood and body fluids leak to the exterior through natural orifices. Once 
outside the host, the vegetative cells convert into spores once again 31. 
Although this disease mainly affects wild and domestic herbivore animals in countries where widespread 
vaccination is not practiced, it also infects humans through contact with infected livestock or animal 
products, such as their skin, hide, meat or bones31. In Africa, Asia and South America, anthrax infection 
remains a severe problem, as humans frequently butcher and eat infected animals 32. The infection can 
be done through cutaneous, gastrointestinal or respiratory routes, each with different mortality rates 31.  
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Owing to its highly pathogenic nature, to the easy production and preservation and to the possibility of 
being aerosolized and sprayed, B. anthracis is considered one of the most lethal biological weapons. In 
fact, methodologies may have been developed for it to be used as a bioweapon in world war I and II. 
More recently, in 2001, B. anthracis was used as a bioterrorism agent – letters deliberately infected with 
B. anthracis were sent to different notables in USA, affecting 22 people 31–34. 
Anthrax is nonfatal in early stages, being treatable with long-term intravenous treatment with quinolones 
and tetracyclines 4. However, it has been reported the existence antibiotic resistant strains of B. 
anthracis, namely to ciprofloxacin, a first line treatment for bacterial infections. What is more, 
antibiotics in the market are ineffective against the spores and the released toxins 1,2.  
 
1.2.3 Antibacterial carbohydrates 
Carbohydrate-based antimicrobials either occur naturally or are semisynthetic and the sugar moiety may 
be the main structural part, such as in the case of aminoglycosides and nucleosides, or it may be attached 
to a non-carbohydrate core structure, for instance, in glycopeptides and macrolides 5,35.  
Structurally, aminoglycosides consist of a six-membered ring aminocyclitol to which are linked several 
amino glycosides (see streptomycin’s structure in Figure 1.7 as example). They are classified as 
bactericidal antibiotics, produced by strains of Actinomycetes species and active against Gram-negative 
bacteria. The general mechanism consists in inhibiting protein synthesis by binding to a ribosomal unit, 
promoting mistranslation and eliminating proofreading (error-correcting processes) 4. More recently, it 
has been detected bacterial membrane damage by streptomycin, a type of aminoglycoside 36. Although 
this type of antimicrobials is not first line treatment for certain infections, by 2004, it was observed that 
80% of hospital-associated methicillin-resistant S. aureus (MRSA, a S. aureus strain multiple drug 
resistant common in hospitals) infections have resistance to multiple aminoglycosides 37. Despite this, 
efforts are being made in the structural modification of aminoglycosides in order to overcome drug 
resistance issues. For instance, FDA recently approved the use of plazomicin (see Figure 1.7) in 
complicated infections caused by the multidrug resistant Enterobacteriaceae 38,39. 
 
 
  
 
 
 
 
 
 
The nucleoside analogues, in turn, are a combination of parts of natural nucleosides conjugated with 
additional structures, amino acids, fatty acids, disaccharides or higher sugars, with the combination 
having antibacterial properties against Gram-positive and Gram-negative bacteria 5,40–42. These 
compounds primarily target a specific translocase (MraY) essential to peptide-glycan biosynthesis and 
Figure 1.7. From left to right, streptomycin and plazomicin’s structure, two aminoglycosides. 
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Figure 1.8. Structure of the nucleoside analogue Zidovudine (AZT) 
consequently cell-wall formation 40–42. Also, due to the fact that nucleoside analogues mimic endogenous 
nucleosides, they may be incorporated in the bacterial DNA/RNA and stop chain elongation, which is 
the case of Zidovudine (AZT, normally prescribed as clinical therapy for HIV, see Figure 1.8) when 
used as antimicrobial agent against Enterobacteriaceae species 41.  This class of compounds has attracted 
attention due to their high efficacy against various pathogenic bacteria including MRSA, and 
vancomycin-resistant Enterococcus. It is worth saying that efforts are being made in order to expand the 
nucleoside-based antimicrobials repertoire41.  
 
 
 
 
 
 
Glycopeptides are another type of carbohydrate based antimicrobial compounds, active against Gram-
positive bacteria. Their structure comprises a cyclic peptide O-glycosylated with mono- or 
disaccharides. One of the most well-known compounds of this class is vancomycin (see Figure 1.9), 
isolated from Amycolatopsis orientalis. The significant lag time between its discovery and the 
appearance of bacteria resistance, due to the lack of cross resistance with other classes of antibacterial 
agents made it an increasingly prescribed therapeutic option. Glycopeptide antibiotics operate by 
inhibiting the assembly of the cell wall peptidoglycan – they bind to a specific peptidoglycan precursor, 
preventing its incorporation into the essential structural cell wall component 5,43. Although vancomycin 
has been the mainstream therapeutic for MRSA infections for decades, other generations of 
glycopeptides were developed. For instance, in 2014, oritavancin (see Figure 1.9), an active compound 
over MRSA and VRSA (vancomycin-resistant S. aureus), was approved by FDA for the treatment of 
skin infections 4.  
 
 
 
 
 
 
 
 
 
 
Finally, the macrolide class of antimicrobials comprises compounds with a macrocyclic lactone O-
glycosylated with one or more deoxy sugars, being either 12-, 14-, 15- or 16-membered ring macrolides. 
They are effective against Gram-positive bacteria, have only limited activity against Gram-negative 
Figure 1.9. From left to right, structure of vancomycin and oritavancin. 
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bacteria and are potent antifungal compounds, namely the polyene macrolides 4. On the first generation 
of macrolides, erythromycin (see Figure 1.10), a 14-membered macrolide, isolated from the 
Streptomyces erythraeus or Arthrobacter, is the best-known compound. Due to poor bioavailability, 
structural changes were made, and other derivatives were synthesized, such as azithromycin (see Figure 
1.10). As the problem of drug resistance remained, the search for other derivatives continued and today 
the only therapeutic macrolide on the marked is telithromycin (see Figure 1.10) 44. Regardless of 
compound’s generation, their antibacterial properties are given by the ability of binding to the 
prokaryotic ribosome and preventing peptide synthesis 5,44. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.4 Novel carbohydrate-based antimicrobials 
Over the years, sugar-based surfactants became an interesting class of compounds, as they have a wide 
range of applications, from detergents to agrochemicals or explosives. Their low toxicity became 
relevant in its application not only in the food and cosmetic industry but also in the pharmaceutical field 
6. In fact, another emerging class of potential synthetic antibiotics are these amphiphilic molecules 4,6–8. 
These compounds comprise a long hydrophobic tail linked to a carbohydrate hydrophilic moiety through 
an ester, amine, amide or glycosidic linkage and are known to be able to interact with the cell membrane 
lipid bilayer 5, thus being worthy of further studies in the field of membrane-targeting antibiotics. 
In fact, our research group has been focused in the study of structure – activity correlation of alkyl 
glycosides as antimicrobial compounds. Several new compounds, belonging to the D series and to the L 
series with α and β configurations were synthesised with different sugar deoxygenation patterns, 
comprising also different alkyl chains (see Figure 1.11).  
Figure 1.10. Above, from left to right, structure of erythromycin and 
azithromycin. Below, structure of telithromycin. 
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The antimicrobial activity of compounds R1 – R12 was primarily accessed by the paper disk diffusion 
method followed by the measurement of the minimum inhibitory concentration value (MIC) of the most 
promising compounds (see 6–8 for more detail). The compounds were tested against several pathogens 
and were active against Gram (+) bacteria, being the best results shown with B. anthracis, B. cereus and 
B. subtilis, E. faecalis and Listeria monocytogenes.  
The most promising MIC values were given by the dodecyl 2,6-dideoxy-L-arabino-hexopyranoside R3 
when tested against B. cereus and B. subtilis, with MIC values (MIC = 7.8 μM in both cases) close to 
the ones of the control (MIC = 3.1 μM and 6.3 μM against B. subtilis and B. cereus respectively). Also, 
this compound proved efficient against E. faecalis (MIC = 15.6 μM) and Listeria monocytogenes (MIC 
= 31.3 μM) 7. 
The compounds were also tested against three different strains of B. anthracis species. In this case, sugar 
derivatives with the 2,6-dideoxy pattern bearing a dodecyl chain with α configuration showed the lowest 
values, being 2,6-dideoxy-L-arabino-hexopyranoside (R3) MIC = 25 μM and 2,6-dideoxy-D-arabino-
hexopyranoside (R7) MIC = 50 μM. On the other hand, the corresponding β anomers (R4 and R8, 
respectively) were inactive against the Bacillus species 8.  
With respect to the 2-deoxy D-glycosides, both octyl and dodecyl β anomers showed MIC values equal 
to 112 μM and 93 μM, respectively, when tested against E. faecalis, being ineffective against the 
Bacillus species 7,8. 
Despite the promising antibacterial activity of the tested compounds, all of them induced toxicity effects 
in peripheral blood human lymphocytes 8. Hence, the next step in the investigation course was not only 
to improve the potency of the analogues but also to lower its toxicity.  
In 2018, Rauter et. al. published a small library of new glycosides bearing a dodecyl chain. O-glycosides, 
C-glycosides and S-glycosides were synthesized, with varying deoxygenation patterns, sugar 
configuration, anomeric configuration and hexopyranoside vs. pentopyranoside structure (see Figure 
1.12) 9,10. 
 
Figure 1.11. Structure of the synthesized compounds by Rauter et. al.. From 
R1 - R4, 2,6-dideoxy-L-arabino-hexopyranosides, from R5 - R8, 2,6-dideoxy-
D-arabino-hexopyranosides and from R9 - R12, 2-deoxy-D-arabino-
hexopyranosides 6–8. 
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Figure 1.12. Deoxyglycosylation pattern of the synthesized compounds by Rauter et. al., bearing a dodecyl chain in the 
anomeric position 6–10. 
2-deoxy O- and S-glycosides 9 were synthesized by a proven method where glycals react with a 
nucleophile in the presence of  triphenylphosphane hydrobromide (TPHB) as catalyst 45. This specific 
catalyst is used in order to minimize the formation of side products resulting from the Ferrier 
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rearrangement (common in acetal protected sugars), namely, the corresponding 3-deoxy sugar 
derivatives (see Scheme 1.3) 45,46. The naturally occurring L-rhamnose, L-fucose, L-xylose and D-xylose 
were used as precursors for the glycal synthesis (see Scheme 1.4). In turn, reaction of the glycals with 
dodecan-1-ol, octan-1-ol or dodecan-1-thiol afforded the desired 2,6-dideoxy L-glycosides (R3, R4, R32 
and R33) and 2-deoxy-threo glycosides from the L- and D- series (R15, R16 and R17, R18, R20, R21, 
respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to afford the 2,6-dideoxy D-glycosides (R7 and R8), Rauter et. al. performed a deoxygenation 
reaction in position 6 in the respective 2-deoxy glycosides. It was accomplished by a tosylation reaction 
with tosyl chloride in pyridine and DCM followed by reduction with LiAlH4 (see Scheme 1.5) 
8. 
 
 
 
 
 
 
Scheme 1.3. Ferrier rearrangement exemplified with compound R3 46. 
Scheme 1.5. Route towards 2,6-dideoxy glycosylation followed by Rauter et. al. exemplified to synthesise compound R7. 
Reagents and conditions: a) dodecan-1-ol, TPHB, DCM, 83%; b) MeONa, MeOH, 95%; c) TsCl, DCM/Py, 93%; d) 
LiAlH4, THF, 79%  
8.  
Scheme 1.4. Synthesis of 2,6-dideoxy L-glycosides, exemplified with R3 and R33 
and 2-deoxy-threo glycosides from the L- and D- series, exemplified with R15 and 
R17, respectively. Reagents and conditions: a) dodecan-1-ol, TPHB, DCM, b) 
NaOMe, MeOH. 
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Likewise, 6-deoxy glycosylation can also be achieved by the iodination of C-6 followed by reduction 
with LiAlH4. This method was applied to afford R25 with 66% yield over two steps 
9. 
The synthesis of the 3-deoxy glycoside R22 could be achieved by taking advantage of the formation of 
the Ferrier rearrangement product, when using a glycal as substrate for the reaction. In this case, the 
glycoside was selectively oxidized in order to introduce an epoxide group at positions 2 and 3, which 
was then selectively reduced with LiAlH4, as depicted in Scheme 1.6 
10. 
 
 
 
 
 
 
Another method followed to obtain 3-deoxy glycosides was the selective protection/deprotection 
strategy of a ribo-hexofuranoside, where positions 4 and 6 and 1 and 2 were protected with 
isopropilidene groups, leaving a free OH group in position 3. The OH in position 3 was triflated and 
reduced with n-Bu4NBH4 to afford the 3-deoxy pentopyranoside R23 as major product and the 
analogous hexopyranoside R22 as a minor product (see Scheme 1.7). This strategy allowed the team to 
have insights on the impact of the furanose ring on the antimicrobial activity over the pyranose ring 10.  
 
 
 
 
 
In order to deoxygenate both 2 and 3 positions at the same time, Rauter et. al. performed a hydrogenation 
reaction of the benzyl protected Ferrier product to afford R26 as depicted in Scheme 1.8 10. 
 
 
 
 
 
In the case of the 3,4-dideoxy glycoside, it was achieved by the selective protection of methyl α-D-
glucose both 2 and 6 positions with a pivaloyl protecting group. The remaining free positions were 
triflated with triflic anhydride and reduced with tetrabutylammonium borohydride to afford the desired 
deoxy pattern. The selective protection of free sugars with pivaloyl esters have been described elsewhere 
47. 
Scheme 1.6. Synthesis of dodecyl 3-deoxy-α-D-ribo-hexopyranoside and 2-deoxy-α-D-ribo-hexopyranoside via epoxide10.  
Reagents and conditions:a) dodecan-1-ol, BF3∙Et2O; b)NaOMe, MeOH, (α, 73% over two steps and β 11% over two steps); 
c)m-CPBA, NaHCO3, DCM, 74%; d)LiAlH4, THF, (R22, 20% and R14, 33%) 
Scheme 1.7. Synthesis of dodecyl 3-deoxy-α-D-ribo-hexopyranoside and -hexofuranoside, via Fisher glycosylation. Reagents  
and conditions: a) Tf2O, py, DCM; b) n-Bu4NBH4, THF, 72% (over two steps); c) TFA, 90%; d) dodecan-1-ol, Amberlyst 15, 
(R23, 28% and R22, 8%)  10. 
Scheme 1.8. Synthesis of dodecyl 2,3-dideoxy-D-erythro-hexopyranoside R26. Reagents and 
conditions: a) dodecan-1-ol, HY, DCE, 43%; b) Et3SiH 10 % Pd/C, 51%. HY refers to a 
specific zeolite and DCE to 1,2-dichloroethane 10. 
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In order to access the 4-deoxy and 4,6-dideoxy pattern, the team proceeded with the regioselective 
protection of both 4 and 6 positions of  methyl α-D-glucopyranoside with an acetal protecting group, 
followed by benzylation of the remaining free positions of the sugar. The regioselective opening of the 
benzylidene group with sodium cyanoborohydride afforded an intermediate compound with an OH 
group in position 4 and a benzyl group in position 6. Deoxygenation of C-4 was accomplished by 
triflation of position 4 followed by its reduction. In order to achieve the 4-deoxy glycoside R34, the co-
workers introduced the dodecyl chain in C-1 and proceeded with the hydrogenation of the benzyl 
protecting groups. After isolating both anomers, the team selectively introduced a triflate group in the 
primary position of the sugar and reduced it with lithium aluminium hydride, affording the 4,6-dideoxy 
O-glycosides R28 and R29 (see Scheme 1.10) 9.  
 
 
 
 
 
 
 
 
 
 
 
C-glycosylation was assessed by an allylation reaction of the acetyl protected substrates followed by a 
metathesis reaction with undecene and a Grubbs type catalyst, to introduce the dodecyl chain in the 
molecule (see Scheme 1.11). The C-glycosides R13, R14, R30 and R31 were obtained by using its 
analogous deoxy O-glycosides acetylated in C-1 9.  
 
 
 
 
Scheme 1.9. Synthesis of the 3,4-dideoxy glycoside R21. Reagents and conditions: PivCl, py, DCM, 65%; b) Tf2O, py, DCM; 
c) n-Bu4NBH4, THF, 29% (over two steps); d) dodecan-1-ol, Amberlyst 15; d) KOH, H2O/MeOH, 36% (over two steps). 
Scheme 1.10. Synthetic route adopted by Rauter et. al. to afford the dodecyl 4-deoxy O-glycosides R34 and 
the dodecyl 4,6-dideoxy O-glycosides R29. Reagents and conditions: a) PhCH(OMe)2, p-TSA, DMF, 94%; 
b) BnBr, NaH, DMF, 82%; c)NaBH3CN, I2, ACN, 77%; d) Tf2O, py, DCM; e) n-Bu4NBH4, THF, 83% (over 
two steps); f) dodecan-1-ol, Amberlyst 15; g) Et3SiH, Pd/C, EtOAc, 80% (over two steps); h) Tf2O, py, DCM; 
i) LiAlH4, THF; g) Ac2O, py, DMAP, 41% (over three steps); j) NaOMe, MeOH, 94-96% 
9.  
Scheme 1.11. Methodology adopted by Rauter et.al. to access the C-glycosides using the corresponding O-glycosides as 
substrate. Here exemplified for R19. Reagents and conditions: a) H2C=CHCH2Si(CH3)3, BF3∙Et2O, ACN, 61%; b) undec-
1-ene, 2nd generation Hoveyda-Grubbs catalyst; c)H2, Pd/C, EtOAc; d) NaOMe, MeOH, 74% (over 3 steps) 
9. 
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The antimicrobial activity of the compounds described was assessed in  B. cereus, E. faecalis and B. 
anthracis strains (sterne, pathonegic and ovine) (see 9,10 for more detailed information). The cytotoxicity 
was also assessed on Caco-2 cells and Hep G2 cells. 
It was found out that 6-deoxy, 2,6-dideoxy and 4,6-dideoxy hexopyranosides were the most active ones 
(the α analogues showed MIC values between 12.6 μM and 56 μM). 4,6-dideoxy α-O-glycoside R28 
was the most promising compound, with MIC = 12.65 μM against all bacteria tested, accounting for half 
of the MIC value of the control against B. anthracis strains (chloramphenicol, MIC = 25 μM). In terms 
of cytotoxicity, the less toxic compounds were the C-glycosides, with IC50 >100 μM on Caco-cells. R28 
showed IC50 = 50 μM over Caco-cells and IC50 >100 μM over Hep G2 cells, although demonstrating 
the highest selectivity of bacteria versus eukaryotic cells 9,10. 
On the structure-activity relationship, it was reported that the α configuration was essential for a good 
bioactivity, as well as the 6-deoxy pattern was crucial for effectiveness over B. cereus and B. anthracis 
Sterne. Also, the C-C linkage not only seemed to benefit D-series bioactivity but also to diminish the 
compounds cytotoxicity. On the other hand, C-3 and C-4 configuration does not appear to have any 
impact on the potency of the compounds. Finally, the furanose form revealed to be less potent when 
compared to the rest of the α-hexopyranosides, although it revealed IC50 = 100 μM 9,10. 
 
The mechanism of action of the synthesized compounds was also investigated and it was proposed the 
carbohydrate – phospholipid interactions to be responsible for the bactericidal activity. It was, in fact, 
demonstrated that these deoxy glycosides’ interactions caused phosphatidylethanolamine (PE) lamellar-
to-inverted hexagonal phase transition, leading to envelope disruption and bacteria cell death in 10 min. 
The selectivity of these glycosides of bacteria cells over eukaryotic cells is explained by the fact that PE 
is abundant in the bacteria cell envelope whereas it is not in animal cells 9. 
The fact that it was not observed the tendency to B. anthracis pore formation as well as any resistance 
mechanism to these deoxy compounds was also an advantage 9. 
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2 Objectives 
 
 
Based on the excellent antibacterial properties exhibited by the 4,6-dideoxy α-O-glycoside R28, 
synthesized by Rauter et. al, the main goal of the presenting dissertation is to obtain the 4,6-dideoxy α-
C-glycoside analogue for further evaluation, aiming to achieving bioactivity towards B. anthracis while 
minimizing compound’s cytotoxicity.  
To attain this purpose, the exploitation of an efficient synthetic route towards the desired C-glycoside is 
the major goal. Different starting materials and protection and deprotection methodologies are 
investigated along this work. Within the synthetic objectives, the first challenge is to obtain the 4,6-
dideoxygenated pattern of the target structure, which will be accomplished with the exploration of 
protection/deprotection strategies in the sugar moiety. The second goal involves the C-glycosylation of 
the dideoxy framework to get the corresponding C-glycoside with α configuration. This constitutes a 
crucial synthetic objective in order to obtain the surfactant mimetic compound. See Scheme 2.1 for 
reactional steps elucidation. 
Structural characterization of intermediates involved in the synthetic pathways and the final compound 
is also a main objective of this work. Deoxygenation pattern, C-C linkage formation, stereogenic center 
configuration and conformation of the synthesized compounds will be evaluated by 1D and 2D NMR 
spectra.  
 
 
 
                                      
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1. General scheme of the steps pursued from two different starting materials in the development of the synthetic 
route towards the dodecyl 4,6-dideoxy glycoside.  
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Synthesis of a C-glycoside with a 4,6-dideoxygenation 
pattern and potential antimicrobial activity  
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3.1 Introduction 
3.1.1 4,6-dideoxy glycosylation methods 
Several mono deoxygenated sugars occur in the nature, such as 6-deoxy-L-mannose (L-rhamnose) and 
6-deoxy-L-galactose (L-fucose), already mentioned in the text. One of the most important deoxy sugars 
in animal life is 2-deoxy-D-ribose, the monosaccharide present in the deoxyribonucleic acid (DNA). On 
the other hand, the only 3-deoxy sugar isolated from natural source is an adenine nucleoside isolated 
from the species Cordyceps, 3-deoxy-D-erythro-pentose. 4-deoxy glycosides haven been reported as 
non-existent in nature, however, it has been identified as a constituent in a lipopolysaccharide of 
Citrobacter specific strain (Citrobacter braakii PCM 1531) 48.  
As for dideoxy sugars, 2,3-, 2,4- and 3,4-dideoxy sugars have not been found in nature. In the case of 
the 2,6-dideoxyhexoses, all of its diastereoisomers have been found in biologically active natural 
products, in some cases linked to flavone type compounds, such as D-oliose (2,6-dideoxy-D-lyxo-
hexose), D-boivinose (2,6-dideoxy-D-xylo-hexose) and D-olivose (2,6-dideoxy-D-arabino-hexose), 
isolated from Rhamnella inaequilatera leaves (see 48 for more insight).  3,6-dideoxy monosaccharides, 
for instance, have been extensively studied in lipopolysaccharides of Gram (-) bacteria – abequose (3,6-
dideoxy-D-xylo-hexopyranose), ascarylose (3,6-dideoxy-L-arabino-hexopyranose), colitose (3,6-
dideoxy-L-xylo-hexopyranose). Curiously, antibodies induced by the vaccine conjugate against Gram (-
) bacteria are quite always directed to target this particular dideoxy hexoses. In turn, 4,6-dideoxy sugars 
rarely occur in nature. Chalcose (4,6-dideoxy-3-O-methyl-D-xylo-hexopyranose), depicted in Figure 
3.1, is a 4,6 dideoxy sugar isolated from chalcomycins or lankamycin (two types of macrolide antibiotics 
produced by Streptomyces sp.). 4,6-dideoxy-D-xylo-hexose (see Figure 3.1) is another 4,6-dideoxy 
analogue found in a macrolide isolated from S. luteoverticillatus. Finally, another naturally occurring 
4,6-dideoxy glycoside is desosamine (4,6-dideoxy-3-dimethylamino-D-xylo-hexopyranose), depicted in 
Figure 3.1, found in the macrolide mycinamicin I 48. 
 
  
 
 
 
 
On the synthesis of these 4,6-dideoxy compounds, it has been described the use of the conventional 
protection/deprotection strategies. Starting from the partially deoxygenated L-rhamnosyl derivative 
protected with a 2,3-O-isopropilidene group, the Barton and McCombie procedure application afforded 
the deoxygenation in position 4, consequently achieving the 4,6-dideoxy pattern (see Scheme 3.1)48,49. 
A Barton McCombie type reaction is a two-step radical reaction where a secondary alcohol is replaced 
by a hydrogen atom, enabling the deoxygenation of a sugar’s secondary positions. Usually, the first step 
comprises the conversion of the alcohol group in an O-thiocarbonyl group, while the second step is the 
radical reaction that replaces the O-thiocarbonyl group by a hydrogen 50. 
 
Figure 3.1. Structure of the naturally occurring 4,6-dideoxy glycosides, D-
chalcose, 4,6-dideoxy--xylo-hexopyranose and desosamine. 
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It has been reported the iodination of both 4 and 6 positions of a methyl glucopyranoside followed by 
its catalytic hydrogenation to achieve the required dideoxy patter, as depicted in Scheme 3.2 48,51. Wessel 
et. al. have also reported the formation of the diiodo glycoside, however they performed the reduction 
reaction with Bu3SnH/AIBN 
52,53.  
 
 
 
 
 
The chlorination of positions 4 and 6 by the Jennings Jones method have also been described. Selective 
chlorination of positions 4 and 6 of methyl α-D-glucose with sulfuryl chloride was achieved followed 
by reduction of both halides with Bu3SnH/AIBN, affording the 4,6-dideoxy glycon as depicted in 
Scheme 3.3 48,54,55. 
 
 
 
 
 
Despite these protection/deprotection methods of sugar moieties in order to obtain 4,6-dideoxy 
glycosylation, methodologies based on the cyclization of diene derivatives have been reported. For 
instance, D-chalcose has been synthesized by a cyclocondensation reaction a silyloxy diene with 
acetaldehyede in the presence of Bf3∙Et2O, as depicted in Scheme 3.4 48,56.  
 
  
 
 
 
More recently, Sun et.al. proposed another example of a synthetic methodology towards D-chalcose by 
using acyclic reagents. They have synthesized D-chalcose and its C-3 epimer by using ethyl (R)-3-
hydroxybutyrate (I) as starting material (see Scheme 3.5). The first step comprised the protection of the 
free OH group with a bulky silyl group, while the second consisted in the reduction of the ester 
functionality to an ether by Dibal-H, affording an aldehyde functionality in the structure (II). Reaction 
Scheme 3.1. Deoxygenation of secondary alcohols, where Pozsgay et al. deoxygenated C-4 by applying the Barton McCombie 
procedure. Reagents and conditions: a) NaH, im, CS2, MeI, THF, 90% yield; b) Bu3SnH, AIBN, 70% yield; c) TFA, 60% 
yield49 ,50 .  
. 
Scheme 3.2. Methodology used by to Siewert et.al in order to afford 4,6-dideoxy glycosylation. 
Reagents and conditions: a) NaI, DMF, 79%; b) H2, Pd, 75%; c) NaOMe, MeOH 
51 .  
. 
Scheme 3.3. Jennings Jones method to afford the 4,6-dideoxy pattern in methyl α-D-glucose. Reagents  
and conditions: a) SO2Cl2, py, CHCl3; b) NaI, MeOH-H2O, 50% (over two steps); c) Bu3SnH, AIBN, 
toluene, 70%. 
Scheme 3.4. Synthesis of D-chalcose through a cyclization strategy, by reaction of a silyloxy 
diene with acetaldehyde. Reagents and conditions:a) Bf3∙Et2O, 89% 48,56. 
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with vinylmagnesium bromide, a Grignard reagent, originated the third intermediate compound (III) 
depicted in Scheme 3.5, which was methylated in the next reactional step (IV). Further reaction with a 
mixture of t-BuOH/H2O in the presence of a specific osmium catalyst used in asymmetric synthesis, 
AD-mix-β 57, afforded the diol intermediate (V). Protection of both free alcohols with -OTBS groups 
followed by selective deprotection of the primary position with camphorsulfonic acid (CSA) made it 
possible to further oxidize the alcohol to aldehyde (by reaction with Dess-Martin periodinane). Posterior 
deprotection of the secondary -OTBS group with TBAF afforded VI which exists in equilibrium with 
its 4,6-dideoxy cyclic form58.  
 
 
 
 
 
 
3.1.2 C-glycosylation methods 
C-glycosylation occurs when a new carbon-carbon bond is formed after reaction at the anomeric centre 
of the sugar. It has been subject of interest due to the occurrence of C-glycosyl compounds in 
glycolipids, oligosaccharides, glycoproteins and natural compounds 59. Compared to the analogous O-
glycosides, the C-glycosides are more stable as than the analogous O- or even S-glycosides, as they are 
inert towards hydrolytic enzymes in vivo. Dapagliflozin, canagliflozin and empagliflozin (compounds 
used against type II diabetes, see Figure 3.2) are examples of biologically active compounds in which 
the C-O glycosidic bond has been replaced by a C-C glycosidic bond in order to synthesize metabolically 
stable species 60. On the naturally occurring C-glycosides, for instance, flavonoids are a class of 
compounds studied by our research group towards the Alzheimer disease 61–63, that have been reported 
to exhibit antibacterial activity 61,63–65. 
 
 
 
 
 
 
 
The glycosyl donors may be methyl glycosides, glycals, glycosyl halides or acetates, 1,2-anhydro 
sugars, lactols or lactones, glycosyl imidates or phosphates or thioglycosides, sulfoxides or sulfones, 
and they can undergo an electrophilic/nucleophilic attack, radical fragmentation, formation of transition 
Scheme 3.5. Strategy employed by the authors to afford D-chalcose and its epimer in C-3, using acyclic intermediates. Reagents  
and conditions: a) TBDPSCl, DMAP, im, DCM, 99%; b) Dibal-H, DCM, 93%; c) vinylmagnesium bromide, CuI, Et2O, 85%; 
d) MeI, t-BuOK, KOH, 96%; e) AD-mix-β, t-BuOH/H2O, 82%; f)TBSOTf, 2,6-lutidine, DCM, 91%; g) CSA, MeOH, 60%; h) 
Dess-Martin periodinane, DCM, 86%, i) TBAF, THF, 83%. Note that AD-mix-β refers to a specific catalyst used in asymmetric 
synthesis 58. 
Figure 3.2. Structures of dapagliflozin, canagliflozin and empagliflozin. 
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metal complexes or rearrangements. Also, the precursors may be acyclic structures that later cyclize to 
give the desired sugar C-glycoside 60. Yang et. al. reviewed all of the C-glycosylation methods used 
between the years 2000 and 2016 60. On the biologically active compounds, Liao et. al. have reviewed 
the C-glycosylation methods employed between the years 2007 and 2017 66. 
Carbohydrates with electrophilic character usually undergo reactions with nucleophilic carbons, where 
both α and β anomers are synthesized in different ratios. Glycosyl halides, -esters and -ethers are 
frequently used as glycosyl donors in C-glycosylation reactions, which can undergo a SN2 or SN1 
pathway. In the case of SN1 reactions, where there is formation of the oxocarbenium cation, the 
stereochemistry is generally controlled by hinderance effects. It is very common the use of zinc reagents 
(R-Zn), organolithium/aluminium (R-Li, R-Al) or Grignard (R-MgBr) derivatives as nucleophiles. 
Although they are effective, the reactional mixtures are air and moisture sensitive, thus difficult to 
manage 66. Cyanides have also been used as nucleophiles - it has been reported the use of KCN as 
nucleophile, to give the cyano-derivative in 39% yield, as exemplified in Scheme 3.6 60,67.   
  
 
 
 
 
 
There was development of the C-glycosylation methods in order to carry out the reactions in milder 
conditions while being also effective. For example, the Fries type glycosylation or the palladium 
catalysed Heck-type C-glycosylation have been reported, where it is used Lewis acids/palladium 
complexes as reaction promoters66.  
A Fries type glycosylation generates a C-glycosylphenol through reaction of a glycosyl donor with a 
phenol in the presence of an activator. This one-pot reaction is useful in the synthesis of flavone 
derivatives and it involves a rearrangement of an O-glycoside to form the C-glycoside, as depicted in 
Scheme 3.7. TMSOTf and BF3∙Et2O are examples of Lewis acids usually used as reaction promoters 68. 
 
 
 
 
 
 
 
Glycosylation reactions involving glycals have already been mentioned in the previous section 1.2.4, 
where it was discussed the formation of O-glycosides (see reaction A, Scheme 3.8). In the case of the 
C-glycosides, carbon nucleophiles should be used as reagents. The Heck-type reaction is a less common 
C-glycosylation reaction, which involves the use of palladium, a transition metal. However it has de 
Scheme 3.6. Synthesis of a C-glycoside by reaction of a halide glycosyl donor and 
KCN in the presence of TBAHS as catalyst 60,67. TBAHS refers to 
tetrabutylammonium hydrogen sulphate. 
Scheme 3.7. Mechanism of the Fries-type rearrangement proposed by Rauter et. al. 68. 
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advantage of being highly effective and with an improved stereocontrol over the products’ 
configuration. Scheme 3.8, reactions A, B and C illustrate different possibilities of palladium catalysed 
C-glycosylations. In particular, a highly stereoselective palladium-catalysed decarboxylative 
glycosylation reaction was used by Liu et. al. in order to synthesize the macrolide aspergillide A with β 
configuration (Scheme 3.9), cytotoxic to leukemia cells 66,69.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Radical fragmentation reactions are also a possible C-glycosylation methodology. It is mostly 
documented to occur when the substrate reacts with Bu3SnH in the presence of AIBN (2,2 -´
azobisisobutyronitrile) as radial initiator 60. In Scheme 3.10 it is illustrated an example of a direct 
allylation of a glycosyl halide in the presence of allyltrimethylstannane in the presence of AIBN 
affording the α anomer as major product in 73% yield 70.  
  
 
 
 
 
Scheme 3.9. Heck-type C-glycosylation reaction used by in the synthesis of the 
macrolide aspergillide A. Reagents and conditions: a) Pd(OAc)2, DiPPF, toluene, 
88%. Note that DiPPF refers to 1,1’- bis(diisopropylphosphino)ferrocene 69. 
Scheme 3.8. General scheme of a typical glycosylation using a glycal as 
substrate in the presence of a Lewis acid as promoter (A) and palladium 
catalysts (B, C, D). 
Scheme 3.10. Synthesis of an allyl glycoside through a radicalar reaction, using a 
glycosyl halide as substrate. Reagents and conditions: allyltrimethylstannane, AIBN, 
73% 70. 
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Herbicidins are a class of nucleoside antibiotics used in plants against Xanthoman oryzae, also embody 
a C-glycosidic bond in its structure. Trauner et. al. reported the synthesis of the C-glycoside Herbicidin 
C through reaction of 1,6-anhydro D-glucose protected with benzyl groups in 2, 3 and 4 positions, with 
allyltrimethylsilane, catalysed by TMSOTf (see Scheme 3.11) 66,71.  
 
 
 
Pluramycins are aryl C-glycosides that besides showing antimicrobial activity also revealed to be active 
against tumors. Suzuki et. al. carried out the synthesis of pluramycin A, where the C-glycosylation 
reaction used the anomeric mixture of the acetyl glycoside as glycosyl donor. The reaction with the 
tricyclic aryl structure in the presence of Sc(OTf)3 to afford the α-C-glycoside in 89% yield 66,72.  
 
 
 
 
 
 
 
Since the mechanistic principles behind the C-glycosylation stereoselectivity is not fully disclosed, the 
search for stereoselective reactions continues to be a major challenge 60,66. 
 
  
Scheme 3.11. C-glycosylation step carried out in the synthesis of Herbicidin C reported Trauner et. al. Reagents and 
conditions: a) allyltrimethylsilane, TMSOTf, 66% 66,71. 
Scheme 3.12. C-glycosylation step carried out in the synthesis of Pluramycin A, reported Suzuki et. al. Reagents and 
conditions: a) Sc(OTf)3, drierite, DCE, 89% 
66,72 . 
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3.2 Results and Discussion 
3.2.1 Synthetic routes 
The purpose of this approach was to explore the capacity of benzoyl group at position 4 of D-glucose as 
leaving group towards a SN2 reaction
80. To do so, we selectively introduced an acetal protecting group 
at positions 4 and 6 of D-glucose – a benzylidene group, followed by benzylation of the remaining 
unprotected positions and finally, regioselective opening of the acetal group with iodosuccinimide 
(NIS), as depicted in Scheme 3.13. 
 
 
 
 
 
 
 
 
 
The use of the benzylidene acetal as a protecting group is a very well-known strategy to selectively 
protect diols. In this case, the reaction was carried out by the addition of benzaldehyde dimethyl acetal 
to a solution of the commercial mixture of α- and β-D-glucose in DMF, in the presence of p-
toluenesulfonic acid (p-TSA). As depicted in Scheme 3.14, it is necessary to use a Lewis acid as a 
catalyst to activate the methoxy groups in the benzaldehyde dimethyl acetal, in order to turn them into 
good leaving groups and consequently promote the nucleophilic attack by one of the free hydroxy 
groups. The mechanism is repeated once again with the other hydroxy group to form the cyclic acetal. 
The solvent choice must take in consideration that in a SN2 reaction, the nucleophilic attack is easier if 
the nucleophile is not solvated. Therefore, it is important to use an aprotic solvent, such as DMF, as it 
will promote the existence of the nucleophile as a “naked anion”, through the prevention of nucleophile-
solvent hydrogen bond interactions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.13. Synthetic route proposal for the synthesis of 19 using D-glucose as starting material. Reagents and conditions: 
a) PhCH(OCH3)2, p-TSA, DMF; b) BnBr, NaH, DMF, 6% over two steps; c) NIS, CCl4, BaCO3. 
Scheme 3.14. Mechanism underlying the protection of positions 4 and 6 of D-glucose with a benzylidene acetal group, where 
HA refers to the Lewis acid used, in this case, p-TSA. 
29 
 
The reaction led to the anomeric mixture which could not be separated as carbon 1 belongs to a 
hemiacetal. By analysis of the 1H NMR spectrum, it was possible to notice the appearance of two 
multiplets between δ 7.34 – δ 7.53 ppm (chemical shift characteristic of phenolic protons), integrating 
in ratio 2:3 protons, in accordance to the presence of a monosubstituted phenol compound. The aromatic 
ring is symmetric and thus one signal is assigned to protons 1 integrating 2H and the other signal 
comprises resonances of protons 2 and proton 3 integrating  3H (see Figure 3.3). Since we were in the 
presence of a mixture of two anomers, in proportion 1:1, the signals integrate to 4 and 6 protons. Also, 
in 13C NMR spectrum, the corresponding carbon signals were duplicated. 
 
 
 
 
 
 
 
 
The spectrum also exhibits a broad singlet at δ 5.59 ppm, integrating 2H, a higher chemical shift than 
the expected for the anomeric proton. As these protons correlate with the aromatic carbons (correlation 
visible in HMBC), it can be confirmed that these signals correspond to the acetal proton H-7 of both 
anomers. Hence, it can be confirmed the presence of the benzylidene group in both α and β anomers. 
While H-7α/β belongs to an acetal function suffering also a deshielding effect caused by the 
neighbouring phenol group, H-1α/β belongs to a hemiacetal, appearing also at higher chemical shift than 
the remaining protons in the sugar moiety. Consequently, it is possible to identify the anomeric protons 
as doublets at δ 5.16 ppm and δ 4.62 ppm. By determining the coupling constants of both signals (J1β,2β 
= 7.88Hz, J1α,2α = 3.10Hz), it was possible to understand which signal corresponds to the α anomer and 
the β anomer, as the coupling constant between H-1α and H-2 is expectedly lower than the one between  
H-1β and H-2 due to the fact that H-1 β and H-2 were trans diaxial to each other, with a dihedral angle 
close to 180º (see Figure 1.4, section 1.1.3, page 5). 
As it was impossible to purify the compounds, that, as hemiacetals, suffer from mutarotation as a result 
of the equilibrium through the acyclic form, the second step of the synthetic route – the benzylation 
reaction, was accomplished using the mixture of the anomers in a well-defined ratio (α:β, 1:1).  
 
To benzilate the remaining free OH groups, sodium hydride was added to a solution of the anomeric 
mixture in DMF. Only after 15 minutes, benzyl bromide was added. The NaH plays an important role 
as it is a strong base and thus it can remove the proton from the OH groups generating anions, facilitating 
the nucleophilic attack to the benzyl bromide (see Scheme 3.15).  
 
 
 
 
 
 
 
 
 
Figure 3.3. Structure of compounds 1a/b  
highlighting numbering of the aromatic protons. 
Scheme 3.15. Mechanism underlying the benzylation reaction. 
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After 3.5h, the TLC revealed the formation of two major products. In this case, the isolation of the 
anomers was possible, but the benzylated anomer was isolated only in 6% yield (yield calculated over 
two steps). When analysing the 1H NMR spectrum, it was possible to confirm the presence of the benzyl 
groups since the integration of the aromatic proton’s signals increased to 20, as well as there were three 
AB systems (between δ 5.01 ppm and δ 4.71 ppm), characteristic of the -CH2 moiety in benzyl groups.  
 
After protecting all the positions of the sugar, the next step was to regioselectively open the benzylidene 
group in order to obtain a benzoyl group at position 4 and position 6 protected with iodide. The main 
goal of this reaction was to investigate the reactivity of the position 4 of the sugar, through a SN2 reaction 
with iodine, with the purpose of easily obtaining the desired 4,6-dideoxy sugar moiety by reduction over 
2 reactional steps after the benzylidene opening reaction, as depicted in Scheme 3.16.  
Since the yield of the benzylation reaction (see Scheme 3.13, step b) was very low, methyl 2,3-di-O-
benzyl-4,6-O-benzylidene-α-D-glucopyranoside (A), already available in our laboratory, was used as 
starting material to be regioselectively opened with NIS (see Scheme 3.16). 
 
 
 
 
 
 
 
 
 
Usually, this type of reaction is performed using NIS, BaCO3 and CCl4 as the solvent and, when needed, 
1,1,2,2-carbon tetrachloride as a cosolvent. At the first attempt, the reaction was carried out using 
chloroform (CHCl3) as solvent, leading to the formation of a complex mixture together with a high 
amount of the remaining starting material (Table 3.1, entry 1). The reaction was repeated in CCl4, 
however, when following the reaction by TLC, the result was similar to the one of the previous attempt 
(Table 3.1, entry 2). The reaction was then repeated several times, in different conditions, as described 
in Table 3.1 (entries 1-4). Since the starting material did not react in an acceptable extent, the reaction 
was repeated using methyl 2,3-di-O-acetyl-4,6-O-benzylidene-α-D-glucopyranoside 4 (see Table 3.1, 
entry 5) and NBS instead of NIS. By TLC, it was possible to observe that the starting material reacted 
completely to give a new compound with lower polarity, in higher amount when compared to the side 
products also formed.  
 
Table 3.1. Reaction conditions to selectively open the benzylidene group. Compound A corresponds to methyl 2,3-di-O-benzyl-
4,6-O-benzylidene-α-D-glucopyranoside, 4 corresponds to methyl 2,3-di-O-acetyl-4,6-O-benzylidene-α-D-glucopyranos ide 
and 5 corresponds to methyl 2,3-di-O-acetyl-4-O-benzoyl-6-bromo-6-deoxy-α-D-glucopyranoside. 
Entry 
Starting 
materiala 
Solvent Reagents Equivalents Time 
Temperature 
/ºC 
Reaction 
outcome 
1 A CHCl3 
NIS 0.95 
20h Reflux 
Complex 
mixture BaCO3 0.95 
2 A CCl4 
NIS 1.1 
20h Reflux 
Complex 
mixture BaCO3 1.1 
3 A CCl4 
NIS 1.1 
30min 66ºC 
Complex 
mixtureb BaCO3 1.1 
4 A NIS 0.95 24h Reflux 
Scheme 3.16. Synthetic route initially designed to obtain the 4,6-dideoxy pattern in 5 reactional steps, starting from 
commercial D-glucose. Reagents and conditions: a) NIS, CCl4, BaCO3; b),LiI, 2,4,6-trimethilpyridine, py
87; c) H2, Pd/C, 
dipea, THF/MeOH. 
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CCl4 + 
CHCl3 
BaCO3 0.95 
Complex 
mixture  
5 4 CCl4 
NBS 1.2 
2.5h Reflux 
Formation of 5 
in 50% yield BaCO3 2.7 
a) Compound A was available at the Carbohydrate Chemistry Laboratory and was not synthesized. 
b) The reaction was carried out in a microwave reactor at 250Psi, 150W. 
 
After purification, when comparing the resulting NMR spectrum of 5 with the starting material 4, it was 
possible to observe that not only the singlet (δ 5.53 ppm) corresponding to the H-7 in the acetal 
protecting group disappeared, but the C-6 chemical shift decreased to δ 31.4 ppm, resulting from the 
shielding effect caused by the presence of the bromide group at the position 6 of the sugar. Also, there 
is a new quaternary carbon signal corresponding to the carbon present in the new carbonyl group. Hence, 
we were able to understand that the new compound was methyl 2,3-di-O-acetyl-4-O-benzoyl-6-bromo-
α-D-glucopyranoside (5).  
In fact, the presence of the benzyl protecting groups seems to be decisive for the reaction, as it did not 
occur with the benzylated sugar derivative. The mechanism underlying this type of benzylidene ring 
opening starts by the abstraction of the acidic proton in the acetal by the halide radical, provided by the 
N-bromosuccinimide. It is followed by the attack of another bromine radical to the least hindered 
position of the acetal, originating the sugar derivative with the halide in position 6 and the benzoyl group 
in position 4 (path 1, Scheme 3.17). Alternatively, it can undergo an ionic pathway, where there is the 
formation of an unstable bromoacetal which suffers fragmentation to a cyclic carbocation and a bromide, 
which in turn attacks the least hindered position of the acetal to give the desired product (path 2, Scheme 
3.17) 81,82. 
However, in this case, it seems that there is competition in the rate limiting step of the reaction (the 
abstraction of the benzylic proton), between the H-7 (acetal proton) and the benzyl ether protons 83,84, 
generating complex mixtures, consuming NBS that is only available to react with a small amount of 
starting material. 
 
 
 
 
 
 
 
 
  
Protection of the positions 2 and 3 of the sugar with acetate protecting groups was not compatible with 
the planned synthetic route, as both acetate and benzoyl groups are esters, and no selectivity is expected 
when performing the following SN2 reaction. Therefore, this synthetic pathway was abandoned and 
synthetic route B adopted. 
 
Scheme 3.17. Possible mechanisms of the oxidative fragmentation of benzylidene acetal 81,82. 
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3.2.2 Other synthetic routes  
After trying other synthetic routes, the intermediate methyl 4,6-dideoxyglycoside was obtained over 8 
steps in 20% overall yield and the target C-glycoside in 13% overall yield starting from methyl α-D-
glucopyranoside. 
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4 Conclusion 
 
The main aim of the present dissertation was accomplished by the synthesis of the new dodecyl 4,6-
dideoxy C-glycoside 19. The first approach was made through a synthetic route starting from the 
naturally occurring D-glucose. Regioselective protection of both 4 and 6 positions followed by 
benzylation of the remaining free positions was achieved with 6% yield over the two steps. The 
regioselective opening of the benzylidene group with N-iodosuccinimide was not successful may be due 
to competition reactions with the benzyl protecting groups in C-2 and C-3. Alternatively, synthetic 
routes were tried, using methyl α-D-glucoside as starting material. After several protection/deprotection 
strategies, dodecyl 4,6-dideoxy-α-D-hexopyranoside 19 was synthesized in 13% yield over 13 synthetic 
steps. 
When compared to the analogue O-glycoside R28 synthesized by Rauter et. al. (15% yield over 11 
steps), the yield was similar. Although achieved through less synthetic steps, the methodology used in 
this work in order to afford the C-glycoside was easier to carry out as the intermediate compounds were 
stable, as well as the hydrogenation reaction mixtures were easily purified through liquid -liquid 
extractions. 
Concluding, it was afforded a new dodecyl 4,6-dideoxy glycoside with potential application as 
antimicrobial compound against B. anthracis with expected lower cytotoxicity than the analogue O-
glycoside R28. Future biological assays will disclose these expectations.   
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5 Experimental 
  
35 
 
5.1 Instrumentation, reagents, solvents and purification techniques 
The reagents used throughout the synthetic route were commercially acquired from Sigma-Aldrich, 
Fischer, Acros and Fluka, as well as the solvents (p.a. grade), with a purity grade prior to 9 8%, as 
mentioned in the label, and were not submitted to any purification before using. In some cases, the 
solvents were dried, prior to use, with activated molecular sieves 3Å. In order to weight the compounds, 
it was used an analytical digital scale from KERN ALJ, 220-4 model, with a ± 10−4g precision. When 
necessary, it was used an ultrasonic bath (VWRTM Ultrasonic Cleaner) to promote the compound’s 
dissolution.  
The reaction’s progression was carried out via TLC plates (20 x 20 cm aluminium sheets coated with 
silica gel, Ref. 60 F254, 0,2 mm thick, purchased from Merck) through UV light detection followed by 
revealing with a H2SO4/MeOH 10% (v/v) solution and heating up to 400ºC. The compounds were 
purified by column chromatography using silica gel (60, 0.040-0.063 mm, purchased from Merck) as 
the stationary phase and a mixture of the adequate solvents as the mobile phase.  
The experimental characterization was accomplished through nuclear magnetic resonance (NMR) 
spectrum with a Bruker Advance 400 spectrometer at 25ºC, operating at 100.62 MHz for 13C NMR and 
400.13 MHz for 1H NMR. CDCl3 and CD3OD (purchased from Sigma-Aldrich) were the solvents used 
to carry out the NMR analysis. The compounds were submitted to 1H NMR, 13C NMR, COSY, HMBC 
and HSQC experiments and the obtained results are expressed as chemical shifts (δ, reported in ppm) 
and coupling constants (J, reported in Hz). The spectra were analysed using either the TopSpin 3.0 or 
MestreNova software. 
The optical rotations ([𝛼]𝐷
20.0) were obtained with a Perkin Elmer 343 polarimeter at 20ºC, with an 
optical percurs of 1cm, using solutions of 10 mg/mL (1c). The melting points were measured on a SMP 
30 capillary apparatus (Stuart Scientific, Bibby). 
 
5.2 Synthesis 
5.2.1 Synthesis of 4,6-O-benzylidene-D-glucopyranose (1a/b). 
 
 
 
 
 
A mixture of D-glucose (0.5 g, 2.78 mmol), benzaldehyde dimethyl acetal (0.46 g, 0.31 mmol), p-
toluenesulfonic acid (0.96 mg, 0.006 mmol) in dry DMF (2 mL) was heated to 60 ºC in a vigorous 
stirring flask, while N2 was being bubbled through the reaction mixture in order to ensure rapid removal 
of the forming MeOH. The reaction was followed by TLC using DCM/MeOH (12:1) as eluent and after 
2.5 h, it was quenched by cooling and adding an excess of Et3N. The solvent was evaporated under 
reduced pressure and it was obtained a syrup which was directly purified by chromatographic column 
using Hex/EtOAc (140:1) as eluent. The mixture of α and β anomers of compound 1a/b (1.72 g) was 
obtained as white crystals in 1:1 ratio. M.p. = 178 ºC – 180 ºC; Rf = 0.35 DCM/MeOH (12:1); 1H NMR 
(CDCl3, 400 MHz): δ 7.52 – 7.51 (m, 4H, H aromatic), 7.37 – 7.35 (m, 6H, H aromatic), 5.59 (s, 2H, H-
7α, H-7β), 5.16 (br d, 1H, H-1α, J1α,2α = 3.10Hz), 4.62 (d, 1H, H-1β, J1β,2β = 7.88Hz), 4.28 (dd, 1H, H-
6βa, J6βa,6βb = 10.62Hz, J5β,6βa = 4.31Hz), 4.20 (dd, 1H, H-6αa, J6αb,6αa = 10.11Hz, J5α,4α = 4.76Hz), 4.00 
(dt, 1H, H-5α),3.89 (t, 1H, H-3α, J3α,4α = J3α,2α = 9.19Hz), 3.80 – 3.72 (m, 2H, H-6βb, H-6αb), 3.65 (t, 
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1H, H-3β, J3β,4β = 8.61Hz), 3.51 – 3.43 (m, 4H, H-4β, H-5β, H-2α, H-4α), 3.26 (dd, 1H, H-2β, J2β,3β = 
8.19Hz). 13C NMR (CDCl3, 400 MHz): δ 137.7 - 126.1 (C aromatic), 101.6, 101.5 (C-7α or C-7β), 97.6 
(C-1β), 93.3 (C-1α), 81.8, 81.1 (C-4β or C-4α), 75.8 (C-2β), 73.3 (C-3β), 73.1 (C-2α), 70.4 (C-3α), 68.9 
(C-6α), 68.4 (C-6β), 66.4 (C-5β), 62.1 (C-5α). Spectroscopic data are in agreement with the literature85. 
 
5.2.2 Synthesis of benzyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside 
(2). 
 
 
 
To a solution of 1a/b (0.21 g, 0.45 mmol) in DMF (4 mL), sodium hydride (60% paraffin suspension, 
0.38 g, 2.23 mmol) was carefully added at 0 ºC and the reaction was stirred for 15 min. Then, benzyl 
bromide (0.04 mL, 2.23 mmol) was added to the mixture and stirred at room temperature for 3.5 h, under 
nitrogen atmosphere. The reaction was quenched by pouring it into cooled water (100mL) and extracted 
with DCM (3 x 100 mL). The organic layers were combined, dried with MgSO4, the solids were filtered 
off and the filtrate concentrated in vacuum. Purification was achieved by chromatographic column, 
using a gradient of Hex/EtOAc (25:1) → Hex/EtOAc (20:1) as eluent, affording the compound 2 (27.10 
mg) as a syrup in 6% yield over two steps.[α]D = -3.7 (c 1.0, CHCl3); Rf = 0.66 Hex/EtOAc (3:1); 1H 
NMR (CDCl3, 400 MHz): δ 7.55 – 7.28 (m, 20H, H aromatic), 5.63 (s, 1H, -OCHPh), 5.02, 4.99 (Part 
A of AB system 1, 1H, -OCH2Ph, JAB = 11.86 Hz), 4.98, 4.95 (Part A of AB system 2, 1H, -OCH2Ph, 
JAB = 11.38Hz)*, 4.97, 4.94 (Part A of AB system 3, 1H, -OCH2Ph, JAB = 10.67Hz)*, 4.86, 4.83 (Part 
B of AB system 2, 1H, -OCH2Ph)*, 4.84, 4.81 (Part B of AB system 3, 1H, -OCH2Ph)*, 4.74, 4.71 (Part 
B of AB system 1, 1H, -OCH2Ph), 4.69 (d, 1H, H-1, J1,2 = 8.26Hz), 4.43 (dd, 1H, H-6a, J6a,5 = 5.07 Hz, 
J6a,6b = 10.36Hz), 3.83 – 3.73 (m, H-3, H-4), 3.87 (t, 1H, H-6b, J6b,5 = 10.19Hz), 3.59 (t, 1H, H-2, J2,3 = 
8.52Hz), 3.48 (td, H-5, J5,4 = 9.68Hz).
13C NMR (CDCl3, 400 MHz): δ 138.5, 138.3, 137.3, 137.1 (Cq 
aromatic), 129.0 – 126.1 (C aromatic), 103.1 (C-1), 101.2 (-OCHPh), 82.2 (C-2), 81.5 (C-3 or C-4), 81.0 
(C-4 or C-3), 75.5 (-OCH2Ph – 3)*, 75.2 (OCH2Ph – 2)*, 71.6 (OCH2Ph – 1), 68.9 (C-6), 66.1 (C-5). 
* permutable  
5.2.3 Synthesis of methyl 4,6-O-benzylidene-α-D-glucopyranoside (3) 
 
 
 
 
 
 
The mixture of methyl α-D-glucopyranoside (5.00 g, 25.74 mmol), benzaldehyde dimethyl acetal (7.84 
g, 51.50 mmol), p-toluenesulfonic acid (0.047g, 0.30 mmol) in dry DMF (25 mL) was heated to 60 ºC 
under a pressure of 240 mbar, in order to continuously remove the MeOH from the reaction mixture. 
The reaction was followed by TLC using Hex/EtOAc (1:3) for 2 h. After total consumption of the 
starting material, the mixture was cooled and extracted with DCM (2 x 300 mL) and water (200 mL). 
The organic layers were combined, dried with MgSO4, the solids were filtered off and the filtrate 
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concentrated in vacuum. Purification was achieved by recrystallization with isopropanol. Compound 3 
(6.54 g) was obtained as white crystals in 90% yield. M.p = 166 ºC - 169 ºC; Rf = 0.22 Hex/EtOAc 
(1:3); 1H NMR (CDCl3, 400 MHz): δ  7.53 – 7.50 (m, 2H, H-aromatic), 7.41 – 7.38 (m, 3H, H-aromatic), 
5.56 (s, 1H, H-7), 4.83 (d, 1H, H-1, J1,2 = 3.76Hz), 4.32 (dd, 1H, H-6a, J6a,6b = 9.55Hz, J6a,5 = 4.35Hz), 
3.97 (t, 1H, H-3, J3,4 = J2,3 = 9.32Hz), 3.87 – 3.85 (m, 2H, H-5, H-6b), 3.67 (dd, 1H, H-2), 3.53 (t, 1H, 
H-4, J4,5 = J3,4 = 9.32Hz), 3.49 (s, 3H, -OCH3). Spectroscopic data in accordance with the literature 
86. 
 
5.2.4 Synthesis of methyl 2,3-di-O-acetyl-4,6-O-benzylidene-α-D-glucopyranoside (4) 
 
 
 
 
To a solution of 3 (6.49 g, 0.02 mol) in pyridine, acetic anhydride (32.58 mL, 0.34 mol) was added 
dropwise at 0 ºC, under nitrogen atmosphere. The reaction was followed by TLC using Cy/EtOAc (2:1), 
at room temperature. After 48 h, the reaction mixture was evaporated under reduced pressure and the 
resulting residue was extracted with DCM (3 x 200 mL) and water (200 mL). The organic layers were 
combined, dried with MgSO4, the solids were filtered off and the filtrate concentrated in vacuum. 
Purification was achieved by recrystallization with ethyl ether, to give compound 4 (6.11 g) as white 
crystals in 80% yield. M.p. = 108 ºC – 109 ºC; [α]D = + 6.7 (c 1.0, CHCl3; Rf = 0.46 Cy/EtOAc (2:1); 
1H NMR (CDCl3, 400 MHz): δ 7.48 – 7.45 (m, 2H, H-aromatic), 7.39 – 7.36 (m, 3H, H-aromatic), 5.61 
(t, 1H, H-3, J3,4 = J2,3 = 9.88Hz), 5.53 (s, 1H, H-7), 4.97 – 4.92 (m, 2H, H-1, H-2), 4.33 (dd, 1H, H-6a, 
J6a,5 = 5.06Hz, J6a,6b = 10.18Hz), 3.95 (t, 1H, H-5, J4,5 = J6b,5 = 9.80Hz), 3.79 (t, 1H, H-6b), 3.67 (dd, 1H, 
H-4), 3.43 (s, 3H, -OCH3), 2.12 (s, 3H, -OCCH3), 2.07 (s, 3H, -OCCH3). Spectroscopic data in 
accordance with the literature 86. 
5.2.5 Synthesis of methyl 2,3-di-O-acetyl-4-O-benzoyl-6-bromo-6-deoxy-α-D-
glucopyranoside (5). 
 
 
 
 
To a solution of 4 (0.14 g, 0.43 mmol) dissolved in CCl4 (6 mL), N-bromosuccinimide (0.09 g, 0.51 
mmol) and barium carbonate (0.23 g, 1.16 mmol), were added under nitrogen atmosphere. The mixture 
was heated under reflux and the reaction was followed by TLC, using Cy/EtOAc (2:1) as eluent. After 
2.5 h, the reaction was cooled, filtered and extracted with DCM (2 x 100 mL) and water (100 mL). The 
organic layers were combined, dried with MgSO4, the solids were filtered off and the f iltrate 
concentrated in vacuum. Purification was achieved by chromatographic column, using Cy/EtOAc (8:1) 
as eluent, to afford compound 5 (0.10 g) as a colourless oil in 50% yield. Rf = 0.55 Cy/EtOAc (2:1), 1H 
NMR (CDCl3, 400 MHz): δ 8.01 (dd, 1H, H-1 ,´ J1´,2´ = 7.13Hz, J1´,3´ = 1.30Hz), 7.61 (t, 1H, H-2´, J2 ,´3´ 
= 7.54Hz), 7.47 (t, 1H, H-3´), 5.71 (t, 1H, H-3, J3,4 = 9.78Hz), 5.20 (t, 1H, H-4), 5.05 (d, 1H, H-1, J1,2 = 
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3.59Hz), 4.98 (dd, 1H, H-2, J2,3 = 10.41Hz), 4.17 – 4.12 (m, 1H, H-5), 3.54 – 3.43 (m, 5H, H-6ab, -
OCH3), 2.10 (s, 3H, -OCCH3), 1.91 (s, 3H, -OCCH3). 
13C NMR (CDCl3, 400 MHz): δ 170.2 (-OCCH3), 
169.9 (-OCCH3), 165.4 (C=O), 133.8 (C-2´), 129.9 (C-1´), 128.7 (C-3´), 96.7 (C-1), 71.6 (C-4), 70.9 
(C-2), 69.5 (C-3), 69.0 (C-5), 55.6 (-OCH3), 31.4 (C-6), 20.8 (-OCCH3), 20.6 (-OCCH3).  
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7 Annexes 
 
 
7.1 Overall synthetic schemes 
 
 
 
 
 
 
 
 
 
  
Scheme 7.1. Starting materials used in approaches 1 and 2 to synthesize C-glycoside 19. 
Scheme 7.3. Detailed approach 1. Reagents and conditions: a) PhCH(OCH3)2, p-TSA, DMF; b) BnBr, NaH, DMF, 
6% yield (over two steps); c) NIS, CCl4, BaCO3. 
Scheme 7.2. General scheme of the steps pursued from two different starting materials 
in the development of the synthetic route towards the dodecyl 4,6-dideoxy glycoside. 
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7.2 NMR spectra 
7.2.1 NMR spectra of 4,6-O-benzylidene-D-glucopyranose (1a/b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7.1. 1H NMR spectrum of compounds 1a/b, in MeOD. 
Figure 7.2. Expansion of the 1H NMR spectrum of compound 1a/b, in MeOD, of the region between δ 3.25 ppm and δ 4.35 ppm. 
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Figure 7.4. COSY spectrum of compounds 1a/b, in MeOD. 
Figure 7.3. 13C NMR spectrum of compounds 1a/b, in MeOD. 
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Figure 7.5. HMBC spectrum of compounds 1a/b, in MeOD. 
 
Figure 7.6. HSQC spectrum of compounds 1a/b, in MeOD. 
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7.2.2 NMR spectra of benzyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-
glucopyranoside (2). 
 
  
Figure 7.7. 1H NMR spectrum of compound 2, in CDCl3. 
Figure 7.8. Expansion of the 1H NMR spectrum of compound 2, in CDCl3, of the region between δ 3.30 ppm 
and δ 5.05 ppm. 
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Figure 7.9. 13C NMR spectrum of compound 2, in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10. COSY spectrum of compound 2, in CDCl3. 
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Figure 7.11. HMBC spectrum of compound 2, in CDCl3. 
 
Figure 7.12. HSQC spectrum of compound 2, in CDCl3. 
50 
 
7.2.3 NMR spectrum of methyl 4,6-O-benzylidene-α-D-glucopyranoside (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.13. 1H NMR spectrum of compound 3, in CDCl3. 
 
  
Figure 7.14. Expansion of the 1H NMR spectrum of compound 3, in CDCl3, of the region between δ 3.45 
ppm and δ 4.40 ppm. 
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7.2.4 NMR spectrum of methyl 2,3-di-O-acetyl-4,6-O-benzylidene-α-D-
glucopyranoside (4).  
Figure 7.15. 1H NMR spectrum of compound 4, in CDCl3. 
Figure 7.16. Expansion of the 1H NMR spectrum of compound 4, in CDCl3, of the region between δ 
3.60 ppm and δ 5.00 ppm. 
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7.2.5 NMR spectra of methyl 2,3-di-O-acetyl-4-O-benzoyl-6-bromo-6-deoxy-α-D-
glucopyranoside (5). 
 
Figure 7.17. 1H NMR spectrum of compound 5, in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.18. 13C NMR spectrum of compound 5, in CDCl3. 
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Figure 7.19. COSY spectrum of compound 5, in CDCl3. 
 
Figure 7.20. HMBC spectrum of compound 5, in CDCl3. 
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Figure 7.21. HSQC spectrum of compound 5, in CDCl3. 
